(NASDAQ:RVPH),
CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences.
Benchmark Healthcare House Call Virtual Investor Conference
Format: Fireside chat and 1×1 investor meetings
Date: Thursday, May 29, 2025
Time: 11:15 a.m. ET
Location: Virtual
Lytham Partners Spring 2025 Investor Conference
Format: Company presentation and 1×1 investor meetings
Date: Thursday, May 29, 2025
Time: 2:00 p.m. ET
Location: Virtual
Webcast Link: Click Here
To arrange a meeting with management please register for the event Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
